If you have been reading about Lyophilization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
In the 1930s and later, epidemiologists from Japan, the UK, and the US, including Richard Doll and various others, reported greater rates of death from lung cancer following occupational exposure to PAH-rich environments among workers in coke ovens and coal carbonization and gasification processes.
Hikmat al-Hijri issued a statement demanding an urgent call for international protection, reiterating the leadership's rejection of any security force entering their areas, the General Security Service and another unidentified agency, accusing them of crossing into the province under the pretext of providing protection while bombing border villages and supporting extremist groups with heavy weaponry and drones. Shelling was reported in the neighboring Daraa Governorate, in which four civilians were wounded by a Druze group from the town of Al-Thaalah and among the villages controlled by Druze groups. Israeli aircraft were seen conducting low-altitude flights over the western countryside of Suwayda, deploying flares, the Israeli Army later announced that it had struck multiple tanks belonging to the Syrian Army in Suwayda Governorate. However a tank was repaired and was deployed again in an hour, The Syrian Arab News Agency reported a total of three Israeli strikes. On 15 July, the Syrian Minister of Defense announced that a ceasefire had been reached with Druze spiritual leadership in Suwayda to cooperate with the Interior and Defense Forces and to surrender their weapons, though it was denied by Hikmat al-Hijri who declared that he would "resist this brutal campaign by all available means", including women, children, and elderly fighting, accusing government forces of violating the ceasefire by shelling Suwayda. Israel conducted further strikes in al-Mazraa after the Syrian Armed Forces took control of the town. Strikes were also reported on the outskirts of Suwayda.
Department of Defense in 2012, when the devices were not yet commercially available and therefore did not require FDA approval. FDA inspection reports from 2014 and 2015 stated that its containers for blood collection were "not validated under actual or simulated use conditions" and "were not reviewed and not approved by designated individual(s) prior to issuance". In 2015, an FDA inspection resulted in multiple observed violations of FDA Title 21 Regulations. It was eventually revealed that the FDA had classified Theranos's device, called a nanotainer, as a Class II medical device, meaning that Theranos would need to use special labels, meet certain performance standards and perform post-market surveillance of the device. Theranos asserted that the nanotainer was a Class I medical device and therefore not subject to any regulatory requirements. After the 2015 inspection, Theranos announced that it would voluntarily suspend its tests apart from the FDA-approved herpes simplex virus (HSV-1) test. The Arizona Department of Health Services reported issues with the company's Scottsdale lab meeting regulations in September 2015. The reports were revealed in the Arizona Republic in November 2015. In January 2016, the Centers for Medicare and Medicaid Services (CMS) sent a letter to Theranos based on a 2015 inspection of its Newark, California lab, reporting that the facility caused "immediate jeopardy to patient health and safety" due to a test to determine the correct dose of the blood-thinning drug warfarin.
Aside from adult transgender people, CPA has also been used as a puberty blocker and hence as an antiandrogen and antiestrogen to suppress puberty in transgender adolescents, although GnRH modulators are primarily used and more effective for this purpose.
The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in coronary arteries following balloon angioplasty. The sirolimus is formulated in a polymer coating that affords controlled release through the healing period following coronary intervention. Several large clinical studies have demonstrated lower restenosis rates in patients treated with sirolimus-eluting stents when compared to bare-metal stents, resulting in fewer repeat procedures. However, this kind of stent may also increase the risk of vascular thrombosis.
Sources: en.wikipedia.org
When allowed to react with superacids, sulfuric acid can act as a base and can be protonated, forming the [H3SO4]+ ion. Salts of [H3SO4]+ have been prepared (e.g. trihydroxyoxosulfonium hexafluoroantimonate(V) [H3SO4]+[SbF6]−) using the following reaction in liquid HF:
While the Rockefeller doctors working in tropical locales such as Mexico emphasized scientific neutrality, they had political and economic aims to promote the value of public health to improve American relations with the host country. Although they claimed the banner of public health and humanitarian medicine, they often engaged with politics and business interests. Rhoads was involved in a racism whitewashing scandal in the 1930s during which he joked about injecting cancer cells into Puerto Rican patients, inspiring Puerto Rican nationalist and anti-colonialist leader Pedro Albizu Campos. Noguchi was also involved in an unethical human experimentation scandal. Susan Lederer, Elizabeth Fee, and Jay Katz are among the modern scholars who have researched this period. Researchers with the foundation including Noguchi developed the vaccine to prevent yellow fever. Rhoads later became a significant cancer researcher and director of Memorial Sloan-Kettering, though his eponymous award for oncological excellence was renamed after the scandal reemerged.
=== 1980s === 1982: Nephrologist Leah Lowenstein became the first woman dean of a co-educational medical school in the United States. 1983: Barbara McClintock received the Nobel Prize in Physiology or Medicine for her discovery of genetic transposition; she was the first woman to receive that prize without sharing it, and the first American woman to receive any unshared Nobel Prize. 1984: Kathryn D. Sullivan becomes the first American woman to walk in space. 1988: Patricia Bath was the first African American woman to receive a medical patent, which was her invention of laser cataract treatment. 1988: Gertrude B. Elion received the Nobel Prize in Physiology or Medicine along with James W. Black and George H. Hitchings "for their discoveries of important principles for drug treatment".
== Further reading == A. Abragam (1961). The Principles of Nuclear Magnetism. Clarendon Press. ISBN 978-0-19-852014-6. {{cite book}}: ISBN / Date incompatibility (help) J.W. Akitt; B.E. Mann (2000). NMR and Chemistry. Cheltenham, UK: Stanley Thornes. pp. 273, 287. ISBN 978-0-7487-4344-5. K.V.R. Chary, Girjesh Govil (2008) NMR in Biological Systems: From Molecules to Human. Springer. ISBN 978-1-4020-6680-1. G.M. Clore; A.M. Gronenborn (1991). "Structures of larger proteins in solution: three- and four-dimensional heteronuclear NMR spectroscopy". Science. 252 (5011): 1390–1399. Bibcode:1991Sci...252.1390M. doi:10.1126/science.2047852. OSTI 83376. PMID 2047852. John Emsley; James Feeney; Leslie Howard Sutcliffe (1965). High Resolution Nuclear Magnetic Resonance Spectroscopy. Pergamon. ISBN 978-1-4831-8408-1. The Feynman Lectures on Physics Vol. II Ch. 35: Paramagnetism and Magnetic Resonance David M. Grant; Robin Kingsley Harris (2002). "Advances in NMR". Encyclopedia of Nuclear Magnetic Resonance. John Wiley. ISBN 978-0-471-49082-1. R.L. Haner; P.A. Keifer (2009). "Flow Probes for NMR Spectroscopy". Encyclopedia of Magnetic Resonance. John Wiley. doi:10.1002/9780470034590.emrstm1085. ISBN 978-0-470-03459-0. J.P. Hornak. "The Basics of NMR". Retrieved 23 February 2009. J. Keeler (2005). Understanding NMR Spectroscopy. John Wiley & Sons. ISBN 978-0-470-01786-9. Gary E. Martin; A. S. Zektzer (1988). Two-Dimensional NMR Methods for Establishing Molecular Connectivity. New York: Wiley-VCH. p. 59. ISBN 978-0-471-18707-3. J.A.Pople; W.G.Schneider; H.J.Bernstein (1959).
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.